Eric Daugas

Prof. Dr. Eric Daugas

Paris University, DMU VICTOIRE, INSERM 1149, Service de Néphrologie, Hôpital Bichat, AP-HP, Paris, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Nature
Verified
Journal Article
Closed access
PDF file
NJNicholas Joza
Nicholas Joza
SSSantos A. Susin
Santos A. Susin
EDEric Daugas
Eric Daugas
WSWilliam L. Stanford
William L. Stanford
SCSarah K. Cho
Sarah K. Cho
JPJosef M Penninger
Josef M Penninger

6 November 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LGLoïc Guillevin
Loïc Guillevin
CPChristian Pagnoux
Christian Pagnoux
AKAlexandre Karras
Alexandre Karras
CKChahera Khouatra
Chahera Khouatra
OAOlivier Aumaître
Olivier Aumaître
LMLuc Mouthon
Luc Mouthon
The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)–associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide–glucocorticoid regimen were randomly assigned to receive either 500 mg of rituximab on days 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22. The primary end point at month 28 was the rate of major relapse (the reappearance of disease activity or worsening, with a Birmingham Vasculitis Activity Score >0, and involvement of one or more major organs, disease-related life-threatening events, or both). The 115 enrolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis) received azathioprine (58 patients) or rituximab (57 patients). At month 28, major relapse had occurred in 17 patients in the azathioprine group (29%) and in 3 patients in the rituximab group (5%) (hazard ratio for relapse, 6.61; 95% confidence interval, 1.56 to 27.96; P=0.002). The frequencies of severe adverse events were similar in the two groups. Twenty-five patients in each group (P=0.92) had severe adverse events; there were 44 events in the azathioprine group and 45 in the rituximab group. Eight patients in the azathioprine group and 11 in the rituximab group had severe infections, and cancer developed in 2 patients in the azathioprine group and 1 in the rituximab group. Two patients in the azathioprine group died (1 from sepsis and 1 from pancreatic cancer). More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov number, NCT00748644; EudraCT number, 2008-002846-51.)

1 October 1996 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SSSantos A. Susin
Santos A. Susin
NZN Zamzami
N Zamzami
MCM Castedo
M Castedo
THT Hirsch
T Hirsch
PMPhilippe Marchetti
Philippe Marchetti
Guido KroemerGuido Kroemer
Guido Kroemer
Bcl-2 belongs to a family of apoptosis-regulatory proteins which incorporate into the outer mitochondrial as well as nuclear membranes. The mechanism by which the proto-oncogene product Bcl-2 inhibits apoptosis is thus far elusive. We and others have shown previously that the first biochemical alteration detectable in cells undergoing apoptosis, well before nuclear changes become manifest, is a collapse of the mitochondrial inner membrane potential (delta psi m), suggesting the involvement of mitochondrial products in the apoptotic cascade. Here we show that mitochondria contain a pre-formed approximately 50-kD protein which is released upon delta psi m disruption and which, in a cell-free in vitro system, causes isolated nuclei to undergo apoptotic changes such as chromatin condensation and internucleosomal DNA fragmentation. This apoptosis-inducing factor (AIF) is blocked by N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk), an antagonist of interleukin-1 beta-converting enzyme (ICE)-like proteases that is also an efficient inhibitor of apoptosis in cells. We have tested the effect of Bcl-2 on the formation, release, and action of AIF. When preventing mitochondrial permeability transition (which accounts for the pre-apoptotic delta psi m disruption in cells), Bcl-2 hyperexpressed in the outer mitochondrial membrane also impedes the release of AIF from isolated mitochondria in vitro. In contrast, Bcl-2 does not affect the formation of AIF, which is contained in comparable quantities in control mitochondria and in mitochondria from Bcl-2-hyperexpressing cells. Furthermore, the presence of Bcl-2 in the nuclear membrane does not interfere with the action of AIF on the nucleus, nor does Bcl-2 hyperexpression protect cells against AIF. It thus appears that Bcl-2 prevents apoptosis by favoring the retention of an apoptogenic protease in mitochondria.

16 August 2001 in Nature Cell Biology
Verified
Journal Article
Closed access
LRLuigi Ravagnan
Luigi Ravagnan
SGSandeep Gurbuxani
Sandeep Gurbuxani
SSSantos A. Susin
Santos A. Susin
CMCarine Maisse
Carine Maisse
EDEric Daugas
Eric Daugas
Guido KroemerGuido Kroemer
Guido Kroemer

1 April 2000 in The FASEB Journal
Verified
Journal Article
Closed access
EDEric Daugas
Eric Daugas
SSSantos A. Susin
Santos A. Susin
NZNaoufal Zamzami
Naoufal Zamzami
KFKarine F. Ferri
Karine F. Ferri
TITheano Irinopoulou
Theano Irinopoulou
Guido KroemerGuido Kroemer
Guido Kroemer

21 August 2000 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SSSantos A. Susin
Santos A. Susin
EDEric Daugas
Eric Daugas
LRLuigi Ravagnan
Luigi Ravagnan
KSKumiko Samejima
Kumiko Samejima
NZNaoufal Zamzami
Naoufal Zamzami
Guido KroemerGuido Kroemer
Guido Kroemer
Apaf-1−/− or caspase-3−/− cells treated with a variety of apoptosis inducers manifest apoptosis-associated alterations including the translocation of apoptosis-inducing factor (AIF) from mitochondria to nuclei, large scale DNA fragmentation, and initial chromatin condensation (stage I). However, when compared with normal control cells, Apaf-1−/− or caspase-3−/− cells fail to exhibit oligonucleosomal chromatin digestion and a more advanced pattern of chromatin condensation (stage II). Microinjection of such cells with recombinant AIF only causes peripheral chromatin condensation (stage I), whereas microinjection with activated caspase-3 or its downstream target caspase-activated DNAse (CAD) causes a more pronounced type of chromatin condensation (stage II). Similarly, when added to purified HeLa nuclei, AIF causes stage I chromatin condensation and large-scale DNA fragmentation, whereas CAD induces stage II chromatin condensation and oligonucleosomal DNA degradation. Furthermore, in a cell-free system, concomitant neutralization of AIF and CAD is required to suppress the nuclear DNA loss caused by cytoplasmic extracts from apoptotic wild-type cells. In contrast, AIF depletion alone suffices to suppress the nuclear DNA loss contained in extracts from apoptotic Apaf-1−/− or caspase-3−/− cells. As a result, at least two redundant parallel pathways may lead to chromatin processing during apoptosis. One of these pathways involves Apaf-1 and caspases, as well as CAD, and leads to oligonucleosomal DNA fragmentation and advanced chromatin condensation. The other pathway, which is caspase-independent, involves AIF and leads to large-scale DNA fragmentation and peripheral chromatin condensation.